CN112914104B - Nutritional composition for preventing obesity in infants - Google Patents

Nutritional composition for preventing obesity in infants Download PDF

Info

Publication number
CN112914104B
CN112914104B CN202110250194.0A CN202110250194A CN112914104B CN 112914104 B CN112914104 B CN 112914104B CN 202110250194 A CN202110250194 A CN 202110250194A CN 112914104 B CN112914104 B CN 112914104B
Authority
CN
China
Prior art keywords
lactobacillus
nutritional composition
weight
oligosaccharide
oligosaccharides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110250194.0A
Other languages
Chinese (zh)
Other versions
CN112914104A (en
Inventor
王园园
陈桔淳
刘斐童
郑雨星
乔纳森·莱恩
曹偲
黎梦樨
黎勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biostime Guangzhou Health Product Co ltd
Original Assignee
Biostime Guangzhou Health Product Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biostime Guangzhou Health Product Co ltd filed Critical Biostime Guangzhou Health Product Co ltd
Priority to CN202110250194.0A priority Critical patent/CN112914104B/en
Publication of CN112914104A publication Critical patent/CN112914104A/en
Application granted granted Critical
Publication of CN112914104B publication Critical patent/CN112914104B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

The present invention relates to a nutritional composition comprising Osteopontin (OPN) and lacto-oligosaccharides, said nutritional composition comprising at least a high concentration of osteopontin, one sialylated oligosaccharide and at least one N-acetylated oligosaccharide, which may be used for the prevention of obesity in infants and young children.

Description

Nutritional composition for preventing obesity in infants
Technical Field
The present invention relates to a nutritional composition comprising osteopontin and specific breast milk oligosaccharides, said nutritional composition comprising at least a high concentration of osteopontin, one sialylated oligosaccharide and at least one N-acetylated oligosaccharide, for use in preventing obesity and promoting healthy growth of infants.
Background
Obesity is a chronic metabolic disease characterized by excessive accumulation of body fat and excess body weight, and is caused by interaction of various factors such as genetic factors and environmental factors. Obesity can lead to an increase in the incidence of metabolic syndrome as well as cardiovascular disease, type 2 diabetes, retinal and renal complications, nonalcoholic fatty liver disease, sleep apnea, polycystic ovary syndrome, infertility, asthma, orthopedic complications, psychiatric disorders and cancer. Earlier obesity may lead to earlier onset of the associated disease. Factors causing obesity in infants are very complex and are related to heredity, nutrition, ethnicity, socioeconomic conditions, caesarean delivery, antibiotics, etc.
Human Milk Oligosaccharides (HMOs) are the third largest solid nutritional component in human milk that is inferior to lactose and lipids. Concentrations in colostrum and mature milk are 22-24g/L and 12-13g/L, respectively, and recently nearly 200 structures have been identified. The core structure of the compound is composed of 5 monomers of N-acetylneuraminic acid (Neu5Ac) derived from galactose (Gal), glucose (Glc), N-acetylglucosamide (GlcNac), fucose (Fuc) and sialic acid (Sia), and the monomers are connected with different groups to generate different effects. The breast milk oligosaccharide can be used as prebiotics, for regulating intestinal flora, as anti-adhesion agent, for resisting pathogen adhesion, and as immune response regulator and for regulating cell inflammatory reaction. The breast milk oligosaccharide can affect various aspects of the growth and development of infants through the mechanism, improve diarrhea, prevent respiratory tract infection, relieve allergy and intervene obesity.
Breast milk HMOs stimulate the growth of certain intestinal flora, which play a role in the childhood obesity pathogenesis by regulating energy absorption, altering metabolic pathways, inducing inflammatory reactions, etc. E.g. butyric acid in short chain fatty acids, which are metabolites of the flora, is an energy source for 70% of the intestinal epithelial cells. Therefore, the infant obesity can be prevented by supplementing breast milk oligosaccharide.
Osteopontin (OPN) is one of the important immunostimulating factors in breast milk, and can promote the maturation of the immune system of infants and protect breast-fed infants from pathogen infection. The OPN can promote the accumulation of macrophages in adipose tissues by mediating the chemotaxis of the macrophages and enhancing the action of Monocyte Chemotactic Protein (MCP) -1, can also cause the increase of adipose tissue inflammatory response factors related to obesity, and plays an important role in the development process of obesity and insulin resistance. However, the regulation effect of OPN on obesity has less published research results, and particularly, the influence on the body weight of infants is not reported.
Disclosure of Invention
It was surprisingly found that a nutritional composition comprising OPN and specific breast milk oligosaccharides has a synergistic effect on the body weight of infants compared to infants fed with conventional nutritional compositions and can be used for preventing obesity in infants.
Accordingly, the present invention provides a nutritional composition comprising OPN and specific breast milk oligosaccharides, said specific breast milk oligosaccharides comprising at least one sialylated oligosaccharide and at least one N-acetylated oligosaccharide.
In a specific embodiment, the specific breast milk oligosaccharides comprise at least two or more of LDFT (lacto-difucotetraose), 3' SL (3 ' sialyllactose), LNT (lacto-N-neotetraose), 2' FL (2-fucosyllactose), and LNnT (lacto-N-neotetraose).
In a specific embodiment, the nutritional composition comprises at least two or more of OPN, LSTc (sialyl-lacto-N-tetraose c), LNT (lacto-N-tetraose), 2 'FL (2' -fucosyllactose), and LNnT (lacto-N-neotetraose).
In a particular embodiment, the mass ratio of Osteopontin (OPN) to total oligosaccharides in the nutritional composition is 1: 20-200.
In a particular embodiment, the sialylated oligosaccharide is present in the nutritional composition in an amount of from 10 to 20% by weight, more preferably the sialylated oligosaccharide comprises sialylated-lacto-N-tetraose c (lstc) in an amount of from 0.2% to 20% by weight of the total weight of the nutritional composition.
In a particular embodiment, the nutritional composition comprises 25% to 50% fucosylated neutral oligosaccharides by weight percentage, more preferably 2-fucosyllactose (2' -FL) comprised in the fucosylated neutral oligosaccharides represents 25% to 50% of the total weight of the nutritional composition.
In a particular embodiment, the nutritional composition comprises 5-35 wt% of neutral oligosaccharides of N-acetylated oligosaccharides, more preferably, the neutral oligosaccharides of N-acetylated oligosaccharides comprise 5-35 wt% of lacto-N-neotetraose (LNnT) and 5-25 wt% of LNT (lacto-N-tetraose) based on the total weight of the nutritional composition.
In a specific embodiment, the nutritional composition is a personalized nutritional composition comprising oligosaccharides at a concentration of 10-10000mg oligosaccharide per 100g nutritional composition.
Another object of the present invention relates to the use of the above nutritional composition.
In a particular embodiment, the nutritional composition is for use in preventing obesity in an infant.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention and not to limit the invention. In the drawings:
FIG. 1T 1 graph comparing breast milk oligosaccharide content in the low and high weight groups over three periods;
FIG. 2T 2 graph comparing breast milk oligosaccharide content in the low and high weight groups over three periods;
FIG. 3T 3 graph comparing breast milk oligosaccharide content in the low and high weight groups over three periods.
Detailed Description
The preferred embodiments of the present invention will be described in conjunction with the accompanying drawings, and it will be understood that they are described herein for the purpose of illustration and explanation and not limitation.
Example 1 relationship between specific types of Breast milk oligosaccharides and infant weight
1 recruiting 28 infant volunteers from hospital, wherein the selection criteria are healthy, term infant (gestational age is more than or equal to 37 weeks), and vaginal delivery; medically proven to be healthy infants: no symptoms and no signs of disease. The mothers of the infants who participated in the experiment will all be informed protocol and guaranteed to be purely breast-fed during the experiment.
2 by collecting mother's milk samples and measuring the weight of the infant during the first month T1(30d + -2 d), the second month T2(60d + -2 d), the third month T3(90d + -2 d) of the infant's age. 28 infants are divided into high-body recombination and low-body weight groups for analysis, the content of 22 oligosaccharides in breast milk of mothers in three periods is measured, and statistics shows that the content of specific types of oligosaccharides in breast milk is related to the weight of the infants.
TABLE 1 infants T1 with significantly different breast milk oligosaccharide species content
Figure BDA0002965706230000041
TABLE 2 infants T2 have significantly different breast milk oligosaccharide species content
Figure BDA0002965706230000042
TABLE 3 significantly different Breast milk oligosaccharide species content for infant T3
Figure BDA0002965706230000043
TABLE 4 significant differences in HMO content in the high and low body weight groups at different periods in breast milk
Figure BDA0002965706230000044
Figure BDA0002965706230000051
As can be seen from table 1 and fig. 1, at T1, the three breast milk oligosaccharides DSLNT, LSTc, LNT all showed significant differences (p < 0.05) between the low and high body weight groups, and the three breast milk oligosaccharides were higher in the low body weight group than in the high body weight group. As can be seen from table 2 and fig. 2, three breast milk oligosaccharides LDFT,3 '-SL and LNT were significantly different (p < 0.05) between the low and high body weight groups at time T2, and wherein LDFT and 3' -SL were higher in the high body weight group than in the low body weight group and LNT was higher in the low body weight group than in the high body weight group. As can be seen from table 3 and fig. 3, there were four breast milk oligosaccharides LDFT,3 '-SL, LSTc, LNT at time T3 that were significantly different (p < 0.05) between the low and high weight groups, where LDFT and 3' -SL were higher in the high weight group than in the low weight group, and LSTc and LNT were higher in the low weight group than in the high weight group. In summary, the high breast milk oligosaccharides in the high body recombination were LDFT and 3' -SL, and the high breast milk oligosaccharides in the low body weight group were DSLNT, LSTc and LNT.
Example 2 prevention of obesity in infants by Breast milk oligosaccharides
It was found from the above studies that breast milk oligosaccharides with high content in the low body weight group were DSLNT, LSTc and LNT. The breast milk oligosaccharide class is associated with the presence of infant body weight. It is envisaged that obesity in infants can be prevented by supplementation with specific breast milk oligosaccharides. The following formulation was then designed and the efficacy of breast milk oligosaccharides was verified by animal experiments.
The obesity prevention verification formula is divided into the following groups:
group 1: 70mg LNT +120mg 2' -FL +100mg LNnT
Group 2: 70mg LSTc +120mg 2' -FL +100mg LNnT
Group 3: 70mg LNT +70mg LSTc +120mg 2' -FL +100mg LNnT
Group 4: 6mg OPN +70mg LNT +70mg LSTc +120mg 2' -FL +100mg LNnT
Control group: 120mg 2' -FL +100mg LNnT
When in use, the formula is prepared into a mixture solution by using warm normal saline, so that the final concentration of oligosaccharide in the solution is 3.9g/L, and the final concentration of OPN in the solution is 65 mg/L.
Kunming male mice with the age of 4-5 weeks are selected, the weight of the Kunming male mice is 20-22g,50 mice are selected, the mice are divided into a control group and 4 test sample experimental groups, and each group comprises 10 mice. The mice are fed with high-nutrition feed in the experimental process. The high-nutrition feed is prepared by adding 10g of milk powder, 10g of lard oil, 1 egg, 10 drops of concentrated cod liver oil and 250g (cut) of fresh soybean sprouts into 100g of common feed, mixing into solid feed and drying. The experimental animals were specifically grouped as follows:
common feed group mice: feeding normal feed for 30 days, and perfusing stomach with normal saline
Control mice: feeding high nutrition feed for 30d, and perfusing stomach with normal saline dissolved with control group formula.
Experimental group 1 mice: feeding high nutrition feed for 30d, and intragastrically irrigating with normal saline dissolved with formula of group 1.
Experimental group 2 mice: feeding high nutrition formulation for 30 days, and intragastrically administering with normal saline solution of formula 2
Experimental group 3 mice: feeding the high nutrition formulation for 30 days, and intragastrically administering with normal saline containing group 3 formulation
Experimental group 4 mice: feeding high nutrition formulation for 30 days, and intragastrically infusing with normal saline containing group 4 formulation
During the experiment, the food intake, food remaining and food intake of each animal were recorded, the weight of the fasting mice was weighed at the beginning and end of the experiment, respectively, the mice were sacrificed by cervical dislocation at the end of the experiment, the total fat around the genitals was stripped off, the fat weight was weighed, and the fat index (g/100g body weight) was calculated.
TABLE 5 mouse body weight measurement results
Figure BDA0002965706230000071
Results 1 (as shown in table 5): there was no statistical difference in food intake for each group of mice during the experiment. The weights of experimental groups 1, 2, 3 and 4 after the experiment are obviously smaller than those of a control group (P is less than 0.05), the weights of mice of the experimental group 4 are smaller than those of the experimental group 1, the experimental group 2 and the experimental group 3(P is less than 0.05), and the weight difference of the experimental group 4 and the experimental group 2 is not significant compared with that of a common feed group.
TABLE 6 measurement results of fat index of mouse
Figure BDA0002965706230000072
Results 2 (as shown in table 6): the fat content of the control group is the most, and the experimental group 1, 2, 3, 4 has uniform and significant difference (P is less than 0.05) with the control group. The fat content of the experimental group 4 is the least, and the experimental group 4 has significant difference (P is less than 0.05) with the control group, the experimental group 1, the experimental group 2 and the experimental group 3, and is close to the common feed feeding group (P is more than 0.05).
The above results indicate that the nutritional composition containing LNT and LSTc can prevent obesity and promote healthy growth of infants; the nutritional composition containing two breast milk oligosaccharides, namely OPN, LNT and LSTc, has synergistic effect on preventing obesity of infants and promoting healthy growth of infants.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.

Claims (6)

1. A nutritional composition for preventing obesity in infants and young children comprising Osteopontin (OPN) and specific breast milk oligosaccharides, wherein the specific breast milk oligosaccharides comprise at least one sialylated oligosaccharide, one fucosylated oligosaccharide, and two N-acetylated oligosaccharides, wherein the sialylated oligosaccharides comprise sialyl-lacto-N-tetraose c (LSTc) and/or 6 '-sialyllactose (6' -SL), the fucosylated oligosaccharide comprises 2 '-fucosyllactose (2' -FL), and the N-acetylated oligosaccharide comprises lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT);
the nutritional composition comprises the following components in percentage by weight:
(1) 10-20% sialylated oligosaccharide in weight percent, wherein sialylated-lacto-N-tetraose c (lstc) comprised in the sialylated oligosaccharide comprises 0.2-20% by weight of the total weight of the nutritional composition;
(2) 25% -50% fucosylated oligosaccharides by weight percentage, wherein the 2 '-fucosyllactose (2' -FL) comprised in said fucosylated oligosaccharides represents 25% -50% of the total weight of the nutritional composition;
(3) 5-35% by weight of N-acetylated oligosaccharides, wherein the N-acetylated oligosaccharides comprise lacto-N-neotetraose (LNnT) in an amount comprised between 5% and 35% by weight of the total weight of the nutritional composition, lacto-N-tetraose (LNT) in an amount comprised between 5% and 25% by weight of the total weight of the nutritional composition;
the mass ratio of the Osteopontin (OPN) to the specific breast milk oligosaccharide is 1: 20-200.
2. The nutritional composition according to claim 1, wherein the total oligosaccharide concentration in the nutritional composition is 10-10000mg oligosaccharide per 100g nutritional composition.
3. The nutritional composition of claim 1, wherein the composition further comprises a prebiotic selected from the group consisting of fructooligosaccharides, inulin, xylooligosaccharides, polydextrose, and any combination thereof.
4. The nutritional composition of claim 3, further comprising a probiotic.
5. The nutritional composition of claim 4, wherein the probiotic is a probiotic strain selected from the group consisting of: lactobacillus acidophilus (Lactobacillus acidophilus), Lactobacillus salivarius (Lactobacillus salivarius), Lactobacillus rhamnosus (Lactobacillus rhamnosus), Lactobacillus paracasei (Lactobacillus paracasei), Lactobacillus casei (Lactobacillus casei), Lactobacillus johnsonii (Lactobacillus johnsonii), Lactobacillus plantarum (Lactobacillus plantarum), Lactobacillus fermentum (Lactobacillus fermentum), Lactobacillus lactis (Lactobacillus lactis), Lactobacillus delbrueckii), Lactobacillus helveticus (Lactobacillus helveticus), Lactobacillus bulgaricus (Lactobacillus helveticus), Lactobacillus lactis (Lactobacillus bulgaricus), Lactobacillus lactis (Lactobacillus lactis), Lactobacillus bifidus (Lactobacillus bifidus), Lactobacillus bifidus (Lactobacillus), Lactobacillus acidophilus (Lactobacillus acidophilus), Lactobacillus thermophilus (Lactobacillus bulgaricus), Bifidobacterium lactis (Bifidobacterium lactis), Bifidobacterium bifidum (Bifidobacterium lactis), Bifidobacterium lactis (Bifidobacterium lactis), and Bifidobacterium lactis (Bifidobacterium).
6. The nutritional composition according to any one of claims 1 to 5, wherein the composition is a solid or liquid formulation.
CN202110250194.0A 2021-03-08 2021-03-08 Nutritional composition for preventing obesity in infants Active CN112914104B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110250194.0A CN112914104B (en) 2021-03-08 2021-03-08 Nutritional composition for preventing obesity in infants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110250194.0A CN112914104B (en) 2021-03-08 2021-03-08 Nutritional composition for preventing obesity in infants

Publications (2)

Publication Number Publication Date
CN112914104A CN112914104A (en) 2021-06-08
CN112914104B true CN112914104B (en) 2021-11-12

Family

ID=76171853

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110250194.0A Active CN112914104B (en) 2021-03-08 2021-03-08 Nutritional composition for preventing obesity in infants

Country Status (1)

Country Link
CN (1) CN112914104B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115399480A (en) * 2021-09-26 2022-11-29 黑龙江飞鹤乳业有限公司 Nutrition composition containing pantothenic acid for promoting neural development and its preparation and application
CN115068591B (en) * 2022-07-06 2023-03-17 合生元（广州）健康产品有限公司 Probiotic composition containing osteopontin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1852665B (en) * 2003-09-18 2010-09-01 阿尔拉食品公司 Infant formula
WO2017129645A1 (en) * 2016-01-26 2017-08-03 Nestec S.A. COMPOSITIONS COMPRISING 2FL AND LNnT TO CONTROL FOOD INTAKE AND GROWTH IN INFANTS OR YOUNG CHILDREN
WO2017129650A1 (en) * 2016-01-26 2017-08-03 Nestec S.A. Compositions comprising 2fl and lnnt for use in infants or young children to prevent later in life obesity or related comorbidities
AU2017211273A1 (en) * 2016-01-26 2018-05-10 Société des Produits Nestlé S.A. Compositions with specific oligosaccharides to prevent later in life obesity or related comorbidities, by increasing colonic SCFA production and/or by increasing GLP-1 secretion
US20210205340A1 (en) * 2016-01-26 2021-07-08 Nestec S.A. Compositions comprising sialylated oligosaccharides for use in infants or young children to prevent later in life obesity or related comorbidities and promote a healthy growth
KR20210005604A (en) * 2018-04-25 2021-01-14 헬쓰 앤드 해피니스 (에이치＆에이치) 홍콩 리미티드 Combination of osteopontin and 2'-fucosylactose for use in medicine
CN111413503A (en) * 2020-03-28 2020-07-14 浙江大学 Application of osteopontin as target molecule in regulating obesity caused by high fat diet

Also Published As

Publication number Publication date
CN112914104A (en) 2021-06-08

Similar Documents

Publication Publication Date Title
Castanys-Muñoz et al. Building a beneficial microbiome from birth
Zhang et al. Human milk oligosaccharides and infant gut microbiota: Molecular structures, utilization strategies and immune function
EP3197295B1 (en) Infant formula system with adaptive levels of human milk oligosaccharides (hmos)
EP2525811B2 (en) A composition comprising lactobacillus rhamnosus hn001 and prebiotics for use in the treatment of allergic lung disease
CN112890200B (en) Nutritional composition for promoting growth pursuit of low-weight infants
CN112914104B (en) Nutritional composition for preventing obesity in infants
EP2563165A1 (en) Use of 6&#39;-sialyl lactose in infant and toddler nutrition
EP2767173A1 (en) Use of human milk oligosaccharides in infant nutrition
AU2017211270B2 (en) Human milk oligosaccharides against later in life excessive fat mass accumulation and related health disorders
WO2011136636A1 (en) Use of 6&#39;-sialyl lactose in infant nutrition
Bertino et al. Metabolism and biological functions of human milk oligosaccharides
Sharma et al. Miraculous health benefits of prebiotics
CN113841898B (en) Prebiotic composition and application thereof in promoting growth of bifidobacterium longum subspecies infantis YLGB-1496
BR112021007646A2 (en) NUTRITIONAL COMPOSITION FOR BABIES FOR USE IN IMPROVING PANCREATIC MATURATION AND INSULIN BIOSYNTHESIS
Morrow et al. Human milk oligosaccharide
Gao et al. Molecular actions of different functional oligosaccharides on intestinal integrity, immune function and microbial community in weanling pigs
Coppa et al. Human milk oligosaccharides as prebiotics
Nallagatla et al. Impact of a novel synbiotic supplementation during gestation and lactation on immune responses in the Swiss albino mice offspring
WO2011136637A1 (en) Use of human milk oligosaccharides in infant nutrition
RU2784624C2 (en) Breast milk oligosaccharides against excessive accumulation of adipose tissue mass in further life and related health disorders
Burrin et al. Advancements in research on necrotizing enterocolitis pathogenesis and prevention using PIGS
Zhao et al. The function of human milk oligosaccharide and its substitute function oligosaccharides as probiotics in gut inflammation
RU2793556C2 (en) Breast milk oligosaccharides for health beneficial effects through prevention of early fat ricochet
CN113862311A (en) Application of combination of isomerized lactose and 2&#39; -fucosyllactose in promoting acid production of Bifidobacterium longum infant subspecies metabolism
Durham Sources and Strategies for Improving the Isolation of Oligosaccharides from Milk and Dairy Streams

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant